跳至主要内容
临床试验/NCT05314374
NCT05314374已完成1 期

Effect of Ileocolic-released Conjugated Bile Acid on Satiety, Entero-Endocrine Cell Function, and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2023年5月12日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
Mayo Clinic
入组人数
35
试验地点
1
主要终点
Glucagon-Like Peptide-1 (GLP-1)

研究概览

简要总结

The purpose of this research is to study the effect of the study drug (a conjugated bile acid dietary supplement) or placebo on cell function, hormones and body weight.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Bile Acid Supplement Group

Experimental

Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements

干预措施: Ileocolonic-release conjugated bile acid (Dietary Supplement)

Placebo Group

Placebo Comparator

Subjects with obesity and abnormal satiety phenotype will receive matching-placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Glucagon-Like Peptide-1 (GLP-1)

时间窗: 90 days

The number of participants that provided a blood sample for GLP-1 (ug/ml) .

Peptide Trosin Tyrosine (PYY) Hormone

时间窗: 90 days

The number of participants that provided a blood sample for PYY.

次要结局

  • Change in Weight(Baseline, 12 weeks)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Andres J. Acosta, M.D., Ph.D.

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验